March 8, 2021
March 8, 2021 | New products and company updates from around Bio-IT including Seven Bridges’ partnership with Pfizer, Illumina’s Russian approval, new methylation detection platform from Twist, and more.
Corteva Agriscience has signed a multi-year agreement with
Genestack to implement and license the use of Omics Data Manager, Genestack’s multi-omics data catalogue, curation and integrative search product. This agreement will facilitate the full utilization of collected research data, enabling insights to help improve the delivery of products, services and solutions to benefit farmers. Omics Data Manager (ODM) will help researchers at Corteva Agriscience accelerate the characterization of novel seed and crop protection solutions through better aggregation of experimental data. ODM provides a single, modern, interface to identify the biological samples of interest across public and internal datasets, which, combined with powerful curation tools, w
MedUX Wins Lever s Berkshire Manufacturing Innovation Challenge iberkshires.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberkshires.com Daily Mail and Mail on Sunday newspapers.
New 3D imaging technique helps detect breast cancer, COVID-19, other diseases
A research team led by UMass Lowell is pioneering a new 3D imaging technique to better detect breast cancer and other diseases, including COVID-19.
The noninvasive medical technology uses specialized contrasting dye that recognizes breast cancer cells, allowing practitioners to better visualize human tissue inside the body. The dye amplifies the X-ray signal in tumors when used together with a state-of-the-art computed tomography (CT) scanner, called a photon-counting spectral CT, which produces multi-colored, 3D images. The contrast agents, combined with spectral CT and machine learning, could lead to a more precise diagnosis of the disease and assist significantly in early intervention, said UMass Lowell Chemistry Assistant Prof. Manos Gkikas, who is leading the project, which is funded by a three-year, $750,000 grant from the Massachusetts Life Sciences Center.
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, today announced a total of $22.4 million in sponsorship commitments for LabCentral 238, a fully functional life sciences laboratory with a focus on scale-up bio-manufacturing. Thermo Fisher Scientific and Waters Corporation join Astellas and the Massachusetts Life Sciences Center (MSLC) as sponsors. Part of the Massachusetts Institute of Technology s (MIT) South of Main Street (SoMa) Development in the heart of Kendall Square s innovation hub, LabCentral 238 is currently under construction and is expected to open in November 2021.
LabCentral 238 co-working laboratory focused on bio-manufacturing (rendering by Encore and Perkins+Will)
LOWELL, Mass. â A research team led by UMass Lowell is pioneering a new 3D imaging technique to better detect breast cancer and other diseases, including COVID-19.Â
The noninvasive medical technology uses specialized contrasting dye that recognizes breast cancer cells, allowing practitioners to better visualize human tissue inside the body. The dye amplifies the X-ray signal in tumors when used together with a state-of-the-art computed tomography (CT) scanner, called a âphoton-counting spectral CT,â which produces multi-colored, 3D images.
âThe contrast agents, combined with spectral CT and machine learning, could lead to a more precise diagnosis of the disease and assist significantly in early intervention,â said UMass Lowell Chemistry Assistant Prof. Manos Gkikas, who is leading the project, which is funded by a three-year, $750,000 grant from the Massachusetts Life Sciences Center.